All News
Spanish COSPAR registry results reveal changes in axSpA pt gut microbiota which are associated with radiographic damage, disease activity, affectation of enthesis and axial mobility. #SAT0362 https://t.co/goo4Qkaqdb #EULAR2020 @RheumNow
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
In regard to biosimilars, what has your experience been? #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
What do you think of #EULAR2020goesvirtual compared to an in person #EULAR? @eular_org @RheumNow @CRASCRRheum #EULAR2020goesvirtual
Janet Pope Janetbirdope ( View Tweet)
#EULAR2020 Friday afternoon command station with my co-worker/health and wellness coach. @KDAO2011 your set up is much better! @RheumNow #bedrest https://t.co/Ldow1eemLZ
Dr. Rachel Tate uptoTate ( View Tweet)
Another study shows that US guided SIJs in axSpA pts are safe and effective. Abstract #AB0642. #EULAR2020 @RheumNow https://t.co/KMPioCKr0n
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
“Let’s consider treating nr-ax SpA and axSpA as serious, similar entities for better treatment options for our patients.” Dr. D. Poddubnyy discussing EXCEED study results and extrapolation of data. #EULAR2020 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI
k dao KDAO2011 ( View Tweet)
#eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0
Olga Petryna DrPetryna ( View Tweet)
I have been impressed with the quality and content of the presentations at #EULAR2020! Here I am trying to navigate the meeting in between telehealth visits at my command center! @RheumNow https://t.co/aGDAr8PPkA
k dao KDAO2011 ( View Tweet)
Big one from plenary, new option in ANCA-associated vasculitis:
avacopan (anti-C5a) vs prednisolone in patients receiving CYC/RTX: non-inf at 26w, superior at 52w in the phase III ADVOCATE trial with reduction in steroid toxicity
Merkel, Jayne et al OP0011 #EULAR2020 @RheumNow
David Liew drdavidliew ( View Tweet)
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
Olga Petryna DrPetryna ( View Tweet)
You might think that steroid exposure in PMR patients wouldn't lead to new comorbidities.
These data beg to differ. New steroid-related comorbidities ++ across domains vs matched controls in real-world US claims data.
We need steroid-sparing in PMR.
OP0271 #EULAR2020 @RheumNow https://t.co/mSzWcJSpfV
David Liew drdavidliew ( View Tweet)
New #therapeutic strategies in #SLE management
#EULAR2020 https://t.co/dhvTKd4EGB
dr hanady manasfi hanadymanasfi ( View Tweet)
Does TCZ actually fix GCA?
@nihrheumatology cohort w serial PET/CT q6m:
FDG uptake (PETVAS) reduces longitudinally over 2y but does not normalise, w rebound on TCZ cessation
Ongoing reductions in year 2? GCA doesn't sleep.
@KQuinnRheum @petercgrayson OP0144 #EULAR2020 @RheumNow https://t.co/aczQbONcNc
David Liew drdavidliew ( View Tweet)
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
Janet Pope Janetbirdope ( View Tweet)
Serum calprotectin as a biomarker in ANCA-associated vasculitis is enticing, and not just during induction:
during maintenance following remission, it might predict relapse and renal decline independently of disease characteristics
MAINRITSAN data OP0031 #EULAR2020 @RheumNow https://t.co/ItI0BPGrUX
David Liew drdavidliew ( View Tweet)
#EULAR2020 OP0167 Results are finally in!!
MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
k dao KDAO2011 ( View Tweet)
So #EULAR2020 was meant to be in Germany, and I was meant to go. I am currently not in Germany.
Germany can come to me!
Just getting into the #EULAR2020goesvirtual spirit @RheumNow https://t.co/RxeTwunR0K
David Liew drdavidliew ( View Tweet)
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
Dr. John Cush RheumNow ( View Tweet)